Drug Manufacturers – Major
(JNJ) Boost for Bayer and Johnson & Johnson
Recently, the US Food and Drug Administration (FDA) delivered a huge boost for Bayer (BAYRY) and partner Johnson & Johnson (JNJ) by...
(LLY) Eli Lilly Provides Research and Development Update
Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for...
(JNJ) Johnson & Johnson Recalls Tylenol Lot
Johnson & Johnson (JNJ) recently announced that it is recalling one lot of Tylenol Extra Strength Caplets, 225 count bottles, at the retail level. The lot, manufactured in Feb 2009, is being recalled in...
(BMY) Bristol-Myers Squibb Expands HIV Drug’s Reach
Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir...
(PFE) Pfizer Drug Accepted for Standard FDA Review
Pfizer Inc. (PFE) recently announced that its regulatory application for oncology candidate, axitinib has been accepted for standard review by the US Food and Drug Administration (FDA). The company is seeking...
(NVS) Novartis AG Afinitor Backed in EU
Novartis AG (NVS) received a boost recently when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of its drug Afinitor for the treatment...
(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of...
(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies
Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated...
(PFE) Pfizer and Pain Therapeutics Get Bad News for Remoxy
The US Food and Drug Administration recently dealt a blow to Pfizer (PFE) and Pain Therapeutics, Inc. (PTIE) by issuing a second complete...
(PFE) Pfizer’s Lyrica Holds Promise
Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central...
(ABT) Abbott Labs Boosts Immunology Pipeline
Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061.
The Candidate: BT-061
The...
(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE:...
(PFE) Pfizer and Acura Pharmaceuticals Win FDA Approval for Oxecta
Pfizer Inc. (PFE) and partner Acura Pharmaceuticals Inc. (ACUR) recently received US Food and Drug Administration (FDA) approval for their...
(NVS) Novartis Gets Setback From FDA Panel
Novartis (NVS) received a setback recently when an advisory panel to the US Food and Drug Administration (FDA) recommended against approving its pipeline candidate ACZ885 for the proposed indication.
Novartis...
(PFE) Pfizer’s Chantix Could Increase Heart Risk
The US Food and Drug Administration (FDA) recently announced that Pfizer’s (PFE) smoking cessation aid Chantix (varenicline) could be linked with a small, increased risk of certain cardiovascular adverse...
(JNJ$) Johnson & Johnson Recalls Risperdal Lot
Johnson & Johnson (JNJ) recently announced that it is voluntarily recalling one lot of Risperdal (risperidone) and one lot of a 2mg generic version of the product. The recalls were based on reports regarding...
(ABT) Abbott Labs’ Bardoxolone in Phase III Trials
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with...
(LLY) Eli Lilly Launches Type II Diabetes Treatment Tradjenta
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the...
(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap
Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys...
(JNJ) Johnson & Johnson to Discontinue Cypher Stent
Cordis Corporation, a Johnson & Johnson (JNJ) company, recently announced that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year end.
The company...
(BMY) Bristol-Myers Squibb Compan Gets Good News
Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(JNJ) Johnson and Johnson Earns FDA Approval for Cancer Drug
Johnson and Johnson (JNJ) recently announced US Food and Drug Administration (FDA) approval for its prostate cancer therapy, Zytiga (abiraterone acetate). Zytiga, an oral, once-daily medication, gained approval...
(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero...
(AZN) AstraZeneca Revenues Fall – Outlook Improves
AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter....
(PFE) Pfizer Tops on Earnings – Misses on Revenues
Pfizer Inc. (PFE) reported first quarter earnings of 60 cents per share, a couple of cents above the Zacks Consensus Estimate, and flat from the year-ago period. First quarter revenues declined 0.4% to $16.5...
(NVS) Novartis Posts Solid First Quarter Sales
Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from...
(MRK) Five Large Cap Pharmaceuticals to Consider
The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change. The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected. Before...
(GSK) GlaxoSmithKline and Valeant Pharmaceuticals Respond to CRL From FDA
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (VRX) recently submitted a response to the Complete Response Letter (CRL) received from...
(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing...